查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496011

全球胰岛素输送设备市场 - 2024 年至 2029 年预测

Global Insulin Delivery Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

胰岛素输送设备市场预计将从 2022 年的 134.71 亿美元增加到 2029 年的 205.31 亿美元，复合年增长率为 6.21%。

受技术进步、对患者的强烈关注以及糖尿病治疗进步的影响，胰岛素输送设备市场持续成长。市场的扩张与糖尿病盛行率的不断上升以及胰岛素发行策略和方法的进步有关。

致命性糖尿病在全球范围内日益占据主导地位，加上依赖胰岛素治疗的儿童糖尿病发病率不断上升，预计未来几年该市场将扩大。据世界卫生组织(WHO)称，糖尿病是约150万人死亡的直接原因，其中48%的糖尿病死亡发生在70岁以下的人群中。此外，2019年全球约20%的心血管疾病是由血糖值升高引起的。

此外，根据2021年12月美国国家医学图书馆的一篇论文，2019年儿童第1型糖尿病的标准化发生率为每10万人中24.7人，到2030年也将达到每10万人中24.7人，预计这一数字将增加至34.8人。 1 型糖尿病患者数量的增加预计将增加对胰岛素的需求，进而扩大全球胰岛素输送设备的市场规模。缺乏胰岛素，加上技术开拓和负担得起的产品供应，预计将在预测期内显着促进胰岛素输送设备市场的成长。

市场驱动因素：

  • 糖尿病人口的增加预计将推动全球对胰岛素输送设备的需求。

由于多种原因，特别是稳定的生活方式、不良饮食和肥胖，全世界糖尿病的盛行率正在增加。这将导致胰岛素治疗和输送设备需求的增加。智慧胰岛素笔和贴片帮浦等创新进步使胰岛素注射变得更容易，对糖尿病患者也更有吸引力。强调以患者为中心的护理将有助于这些设备的选择，促进和提高生活质量，减少注射负担，并提高治疗依从性。

此外，2021年11月，国际糖尿病联盟发布的报告指出，全球约有5.37亿人患有糖尿病，比2019年的数字增加了16%。报告也估计，中国和印度等人口大国的糖尿病患者人数最多，成年人口分别约 1.41 亿和 7,400 万人。

此外，根据 IDF 的数据，印度约 53.1% 的糖尿病患者患有未确诊的糖尿病，另有 4,000 万人患有葡萄糖耐受不良(IGT)。这增加了罹患第 2 型糖尿病的风险，增加了对胰岛素的需求，并开拓了胰岛素输送设备的市场。

根据 2021 年世卫组织全球糖尿病契约报告，低收入和中等收入国家中 50% 的第 2 型糖尿病患者无法获得胰岛素，而需要在 39% 的医疗机构中使用人类胰岛素。预计这些方面将透过在所需国家提供胰岛素设备来提高市场参与者的渗透率。

  • 不断进步的技术可能会增强对胰岛素输送设备的需求。

科技的进步正在推动对先进胰岛素输送设备的需求。其中包括智慧胰岛素笔、连接的连续血糖监测系统、闭合迴路的贴片帮浦帮浦、无针喷射注射器、植入式帮浦、人工胰臟系统、双腔室设备、生物相容性材料、先进的输液器和资料整合、云端连接、可自订的剂量演算法等等。这些进步提高了胰岛素给药的有效性、便利性和使用者体验。

此外，资讯来源称，160 万美国人患有第 1 型糖尿病，该地区每天诊断出 100 多例病例。预计在预测期内，对抗第 1 型糖尿病和促进胰岛素使用的技术开拓将为市场参与者提供利润丰厚的市场机会。

主要进展

  • 2023年6月－诺和诺德与BIO JAG谈判收购BIOCORP股份（占股本45.3%，理论投票权62.2%）。收购完成后，将对所有剩余的 BIOCORP 证券进行简短要约收购，如果满足法律要求，将强制挤出剩余股东并使 BIOCORP 退市。 BIOCORP 是一家法国公司，专注于输送系统和创新医疗设备，包括用于笔式註射器的蓝牙智慧附加元件设备 Mallya。
  • 2023 年 2 月 - 礼来公司宣布将以低成本向国际机构（孟加拉）有限公司（IABL）供应人类胰岛素 API。 (IABL) 宣布将以更低的价格供应人类胰岛素原料药，以提高到 2030 年孟加拉约 100 万名糖尿病患者的负担能力和可及性。 IABL 计画到 2025 年，根据世界卫生组织 (WHO) 全球糖尿病契约，专用孟加拉国市场生产和完成自有品牌的人类胰岛素管瓶和药筒。
  • 2022 年 11 月 -Medtronic)开发了一种系统，可以使患者佩戴胰岛素泵输液器的时间增加一倍，由于瘙痒和瘀伤等问题，患者通常每两到三天更换一次胰岛素泵输液器。此系统使用的材料可减少胰岛素防腐剂流失并保持药物流动和稳定性。该系统在临床试验中得到检验，第 7 天结束时的存活率为 77.8%。
  • 2022 年 4 月 - Insulet 的 Omnipod 5 获得 FDA 批准，这是首款适用于 6 岁及以上 1 型糖尿病患者的无管、可穿戴、自动化胰岛素输送系统。该系统使用 Dexcom 的 G6 连续血糖监测 (CGM) 系统来提供更轻鬆的血糖管理，而无需使用每日多次注射、试管和指尖采血。患者可以使用手持控制器或安全的智慧型手机应用程式控制系统。临床研究表明，范围时间得到改善，糖化血红蛋白水平降低。 Omnipod 5 每 5 分钟发送一次 Dexcom CGM 值，并预测接下来 60 分钟的血糖值。

提供的产品

  • 诺和诺德 (Novo Nordisk) A/S 的 NovoPen(R) 4 - NovoPen(R) 4 是一款易于使用的胰岛素泵，具有坚固的设计，可确保准确无忧的剂量，以及可在需要时可轻鬆更换，并发出喀喀声。剂量选项是 3 毫升笔筒，最多可输送 60 单位的胰岛素。
  • T:slimX2 胰岛素帮浦 - T:slimX2 胰岛素帮浦是 Tandem 的产品，是一种先进的现代设备，最多可容纳 300 单位的胰岛素。它具有彩色触控萤幕、个人化设定、可充电电池和断开连接功能。透过与相容的 CGM 感测器配对，您可以实现自动胰岛素给药系统。 Control-IQ 技术根据感测器读数提前 30 分钟预测血糖水平，并根据需要自动调整胰岛素，使糖尿病管理变得更加容易。

主要市场区隔

胰岛素输送设备市场细分与分析如下：

按类型

  • 注射器
  • 胰岛素帮浦
  • 吸入器
  • 其他的

按用途

  • 一型糖尿病
  • II型糖尿病
  • 妊娠糖尿病

按最终用户

  • 医院和诊所
  • 门诊护理中心
  • 居家照护环境

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
  • 中东和非洲
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 日本
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章胰岛素输送设备的全球市场：按类型

  • 介绍
  • 注射器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胰岛素帮浦
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 吸入器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球胰岛素输送设备市场：依应用分类

  • 介绍
  • 1型糖尿病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 2型糖尿病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 妊娠糖尿病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章胰岛素输送设备的全球市场：依最终用户分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊治疗中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 居家照护设置
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球胰岛素输送设备市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按用途
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 有竞争力的仪表板

第十章 公司简介

  • Novo Nordisk A/S
  • Beckton, Dickinson and Company
  • Medtronic
  • Sanofi
  • Eli Lilly and Company
  • Ypsomed AG
  • Biocon Limited
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • F. Hoffman-La Roche Ltd.
简介目录
Product Code: KSI061612023

The global insulin delivery devices market is estimated to witness a compound annual growth rate of 6.21% and reach US$20.531 billion by 2029, up from US$13.471 billion in 2022.

The market of insulin delivery devices is continuously rising with the impact of advances in technology, persistent patient inclinations, and the advancing diabetes care aspects. The market's expansion is connected to the expanding prevalence of diabetes and endeavors to progress insulin delivery strategies and methods.

The rising predominance of diabetes resulting in fatalities all over the world, coupled with expanding occurrences of childhood diabetes subordinate to insulin for care, is expected to move the market extension within the years ahead. As per the World Health Organization (WHO), diabetes was the straightforward cause of about 1.5 million deaths, and 48% of deaths coming from diabetes happened before the age of 70. Furthermore, raised blood glucose caused around 20% of cardiovascular illnesses around the world in 2019.

Furthermore, as per the National Library of Medicine article of December 2021, the standardized incidence of type 1 diabetes in children was 24.7 per 100,000 in 2019, which is also expected to rise to 34.8 per 100,000 PY in 2030. This rise in the number of type-1 diabetes individuals is predicted to boost the requirement for insulin, which in turn expands the market size of insulin delivery devices globally. Technological developments coupled with affordable product availability along with lack of access to insulin are together anticipated to push the market growth for insulin delivery devices at a significant scale during the forecast period.

Market Drivers:

  • The growing diabetic population is expected to boost the demand for insulin delivery devices globally.

The predominance of global diabetes is increasing because of various causes specifically, due to stationary lifestyles, poor diet, and obesity. This will lead to a rising request for demand in insulin treatment and delivery devices. Innovative advancements like smart insulin pens and patch pumps make administrating of insulin more user-friendly and engaging to diabetic patients. The accentuation on patient-centric care is driving the selection of these devices, promoting and providing a progressed quality of life, decreased injection burden, and improved treatment adherence.

Additionally, in November 2021 a report was released by the International Diabetes Federation that stated about 537 million individuals are living with diabetes around the world, which is an increment of 16% from the 2019 numbers. The sources also inferred that populated nations such as China and India have the most noteworthy number of diabetic individuals, with an adult population of about 141 million and 74 million within the nation.

Besides, as per the IDF, around 53.1% of the diabetic Indian populace is undiscovered for diabetes, with an extra 40 million individuals living with impaired glucose tolerance (IGT). This could cause a higher risk of developing type 2 diabetes, in this manner expanding the demand for insulin, coming about within the market expansion of insulin delivery devices as well.

As per the 2021 WHO Global Diabetes Compact Report, there's a absence of insulin accessibility to 50% of the individuals with type 2 diabetes, and a need of human insulin in 39% of the healthcare facilities in low- and middle-income nations. Aspects such as these are projected to offer market players increased penetration by offering insulin devices in the needed countries.

  • Rising technological advancement would bolster the demand for insulin delivery devices.

Technological advancements are driving the demand for advanced insulin delivery devices. These include smart insulin pens, connected continuous glucose monitoring systems, patch pumps with closed-loop systems, needle-free jet injectors, implantable pumps, artificial pancreas systems, dual-chamber devices, biocompatible materials, advanced infusion sets, data integration, cloud connectivity, and customizable dosing algorithms. These advancements enhance the effectiveness, convenience, and user experience of insulin administration.

Additionally, as per the source, 1.6 million Americans live with Type 1 diabetes, and more than 100 cases are diagnosed daily in the region. The development of technologies for battling type-1 diabetes and promoting insulin use is projected to offer the market players profitable market opportunities in the forecasted period.

Key Developments:

  • June 2023- Novo Nordisk negotiated with BIO JAG to acquire its entire stake in BIOCORP, which represents 45.3% of its share capital and 62.2% of its theoretical voting rights. The acquisition followed by a simplified tender offer on all remaining outstanding BIOCORP securities, and if legal requirements are met, a mandatory squeeze-out of remaining shareholders and delisting of BIOCORP. BIOCORP is a French company specializing in delivery systems and innovative medical devices, including the Bluetooth-enabled smart add-on device for pen injectors, Mallya.
  • February 2023- Eli Lilly and Company stated the supply of its API for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) to improve affordability and access for nearly one million people with diabetes in Bangladesh by 2030. IABL plans to manufacture and finish human insulin vials and cartridges under its own brand name by 2025, exclusively for the Bangladesh market, in line with the World Health Organization's Global Diabetes Compact.
  • November 2022- Medtronic developed a system to double the wear time of insulin pump infusion sets, which patients typically change every two to three days due to issues like itching and bruising. The system uses materials to reduce the loss of insulin preservatives and maintain drug flow and stability. The system was validated in clinical trials, with a survival rate of 77.8% at the end of day seven. The company believes the extended-wear system can reduce cost and plastic waste, with users changing their devices 75 fewer times, resulting in annual savings of over $1,000.
  • April 2022- Insulet received FDA clearance for its Omnipod 5, the first tubeless, wearable, automated insulin delivery system for individuals aged six and older with type 1 diabetes. The system uses Dexcom's G6 continuous glucose monitoring (CGM) system and offers easier glucose management without multiple daily injections, tubes, or fingersticks. Patients can control the system with a handheld controller or a secure smartphone app. Improved time in range and lower levels of glycosylated hemoglobin were seen in a clinical investigation. Every five minutes, the Omnipod 5 transmits a Dexcom CGM value and forecasts the glucose levels for the next sixty minutes.

Product Offered:

  • NovoPen(R) 4- NovoPen(R) 4 from Novo Nordisk A/S is a user-friendly insulin pump with a robust design that ensures accurate and reassuring dose delivery and features an audible end-of-dose click for ease of use and change when needed. The dosing option is a 3ml pen fill cartridge that can deliver up to 60 units of insulin at a maximum dose. Its robust design lasts up to 5 years.
  • T:slim X2 insulin pump- The t:slim X2 insulin pump is a product from Tandem, it is a sophisticated, modern device that can hold up to 300 units of insulin. It features a color touchscreen, personalized settings, a rechargeable battery, and the ability to disconnect. It can pair with a compatible CGM sensor for an automated insulin delivery system. Control-IQ technology uses sensor values to predict glucose levels 30 minutes ahead and automatically adjust insulin if needed, making diabetes management easier.

Key Market Segmentation:

Global Insulin Delivery Devices Market is segmented and analyzed as below:

By Type

  • Syringes
  • Insulin Pumps
  • Inhalers
  • Others

By Application

  • Type I Diabetes
  • Type II Diabetes
  • Gestational Diabetes

By End-Users

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Home Care Settings

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Other

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL INSULIN DELIVERY DEVICES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Syringes
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Insulin Pumps
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Inhalers
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL INSULIN DELIVERY DEVICES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Type I Diabetes
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Type II Diabetes
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Gestational Diabetes
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL INSULIN DELIVERY DEVICES MARKET BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Home Care Settings
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL INSULIN DELIVERY DEVICES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End-Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End-Users
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End-Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End-Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Novo Nordisk A/S
  • 10.2. Beckton, Dickinson and Company
  • 10.3. Medtronic
  • 10.4. Sanofi
  • 10.5. Eli Lilly and Company
  • 10.6. Ypsomed AG
  • 10.7. Biocon Limited
  • 10.8. Insulet Corporation
  • 10.9. Tandem Diabetes Care, Inc.
  • 10.10. F. Hoffman-La Roche Ltd.